This finding was supported by one study that illustrated that the reduction of ABCG2 expression was due to the methylation of its promoter by the action of melatonin combination with temozolomide in BTSCs and A172 malignant glioma cells (Martín et al. 2013). Here, ABCG2 is linked to malignant glioma.